Business Wire

THALES

21.9.2022 10:09:38 CEST | Business Wire | Press release

Share
Confidence in Addressing Security Challenges of Hybrid Work Improving Among Businesses, Finds Thales

With the past two years resulting in a permanently altered working environment, changes in security were both necessary and notable. Controlling access to applications, data, and systems is an increasingly important aspect of securing any environment and protecting it against both internal and external threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

After two years of the pandemic, confidence in addressing certain security risks and threats arising from hybrid and remote work has improved among businesses and organizations around the world. When it comes to secure access to applications, data, and systems, 84% IT professionals this year said they have some degree of confidence in their current user access security systems to enable remote work securely and easily, compared to 56% in 2021. In addition, 60% said this year they were highly confident compared to just 22% last year.

These are among some of the key findings from the 2022 Thales Access Management Index, a global survey of 2,600 IT decision makers, conducted by 451 Research, part of S&P Global Market Intelligence.

Firms Gaining Confidence Addressing Security of Remote Work
Overall, the report findings suggest that firms remain concerned about the security risks of remote work, but those concerns seem to be less severe. At the same time, firms are also growing more confident in the ability of authentication and access management systems to manage those risks. Only 31% of IT professional surveyed reported having “very high” concerns about the security risks and threats of remote work in 2022, down from 39% in 2021, while those who said they were “somewhat concerned” – the most popular response – increased from 43% to 48% in 2022.

Multi-Factor Authentication on the Rise But Not Widespread
While multi-factor authentication (MFA) usage remains most prevalent for remote workers (68%) and privileged users (52%), the report shows that MFA adoption is on the rise for internal and non-IT staff with MFA adoption increasing to 40% compared to 34% in 2021. However, widespread MFA adoption by businesses is still yet to be the norm with just over half (56%) have adopted MFA in their organizations.

Lingering Effects of Pandemic Drive Interest in Access Management, MFA and ZTNA
The survey inquired about direct impacts that the pandemic and remote work had on deployment plans for new access security technologies. Responses revealed a six-percentage-point global increase in plans to deploy stand-alone MFA, up from 31% in 2021. The pandemic also impacted plans to deploy cloud-based access management, selected by 45% of respondents worldwide compared to 41% in 2021. These two increases illustrate respondents’ growing awareness that threats come from all angles, and that proper authentication and management of access and privileges is necessary for an adequate security foundation. Last year, Zero Trust Network Access/Software-Defined Perimeter (ZTNA)/(SDP) was the top choice, selected by 44% of respondents. In 2022, ZTNA was the second choice at 42%.

Francois Lasnier, Vice President of Access Management Solutions at Thales comments: “The past few years have cemented remote work and work-from-anywhere as a permanent part of the security landscape, and they have also introduced new security risks and challenges. However, growing familiarity with remote work has ultimately broadened awareness on an enterprise level of daily business security risks and has strengthened both confidence and ability in security teams and products to handle those risks and threats properly.”

Garrett Bekker, Principal Analyst at 451 Research comments:Just as the threat landscape has evolved, the tools and methods to handle the landscape have, too. However, even with innovative tools and boosted confidence levels, security plans and approaches still need to adapt to the ever-changing threat environment. A greater shift towards a Zero Trust model would place access management in a central role in corporate security strategies, with a related reliance on MFA as a critical supporting enabler.

Thales and 451 Research will discuss the findings in more detail during a webinar on 29 September 2022. To join, please visit the registration page.

About the 2022 Thales Access Management Index
As organizations step beyond the urgent actions of the last two years, they’re grappling with securing the more complex environments in which they now operate. The global edition of the 2022 Thales Access Management Index looked at various aspects of those impacts in a wide-ranging survey of security professionals and executive leadership that touched on issues including access management and access security, multi-factor authentication, zero-trust network access, security spending plans, remote work and VPNs, and ransomware. The 2022 Thales Access Management Study is based on data from a survey of nearly 2,800 security professionals and executive leaders in more than 15 countries across the globe. This research was conducted as an observational study and makes no causal claims.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Group
Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005005/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye